These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28546089)

  • 21. Long-acting Cabotegravir Shot Prevents HIV Among Women.
    Abbasi J
    JAMA; 2020 Dec; 324(22):2247. PubMed ID: 33289810
    [No Abstract]   [Full Text] [Related]  

  • 22. Cabotegravir Sodium.
    Am J Health Syst Pharm; 2021 May; 78(11):920-924. PubMed ID: 33821887
    [No Abstract]   [Full Text] [Related]  

  • 23. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
    Kerrigan D; Mantsios A; Gorgolas M; Montes ML; Pulido F; Brinson C; deVente J; Richmond GJ; Beckham SW; Hammond P; Margolis D; Murray M
    PLoS One; 2018; 13(1):e0190487. PubMed ID: 29304154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor.
    Cattaneo D; Gervasoni C
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):319-327. PubMed ID: 30387005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
    Shaik JSB; Ford SL; Lou Y; Zhang Z; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):664-673. PubMed ID: 30811880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
    Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
    Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
    McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.
    Rusconi S; Marcotullio S; Cingolani A
    New Microbiol; 2017 Apr; 40(2):75-79. PubMed ID: 28368071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
    Lou Y; Buchanan AM; Chen S; Ford SL; Gould E; Margolis D; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):509-516. PubMed ID: 27162089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
    Stellbrink HJ; Hoffmann C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants.
    Parasrampuria R; Ford SL; Lou Y; Fu C; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):674-681. PubMed ID: 30809978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting antiviral agents for HIV treatment.
    Margolis DA; Boffito M
    Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
    Bowers GD; Culp A; Reese MJ; Tabolt G; Moss L; Piscitelli S; Huynh P; Wagner D; Ford SL; Gould EP; Pan R; Lou Y; Margolis DA; Spreen WR
    Xenobiotica; 2016; 46(2):147-62. PubMed ID: 26134155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
    Andrews CD; Bernard LS; Poon AY; Mohri H; Gettie N; Spreen WR; Gettie A; Russell-Lodrigue K; Blanchard J; Hong Z; Ho DD; Markowitz M
    AIDS; 2017 Feb; 31(4):461-467. PubMed ID: 27902508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
    Patel P; Ford SL; Lou Y; Bakshi K; Tenorio AR; Zhang Z; Pan R; Spreen W
    Clin Pharmacol Drug Dev; 2019 May; 8(4):443-448. PubMed ID: 30230694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.
    Whitfield T; Torkington A; van Halsema C
    HIV AIDS (Auckl); 2016; 8():157-164. PubMed ID: 27799824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment and prevention of HIV infection with long-acting antiretrovirals.
    Benítez-Gutiérrez L; Soriano V; Requena S; Arias A; Barreiro P; de Mendoza C
    Expert Rev Clin Pharmacol; 2018 May; 11(5):507-517. PubMed ID: 29595351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.